Hematopoietic stem cell transplantation using single UM171-expanded cord blood
                         CML - Chronic myeloid leukemia

                                                                                                                                       Français
''Benefits of cord blood transplantation include low rates of relapse and chronic graft-versus-host disease (GVHD). However, the use of cord blood is rapidly declining because of the high incidence of infections, severe acute GVHD, and transplant-related mortality. UM171, a haematopoietic stem cell self-renewal agonist, has been s​hown to expand cord blood stem cells and enhance multilineage blood cell reconstitution in mice. We aimed to investigate the safety and feasibility of single UM171-expanded cord blood transplantation in patients with haematological malignancies who do not have a suitable HLA-matched donor.''
​Extract of  Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
"In their new study, the IRIC researchers found to their great surprise that UM171 is able to act as a veritable “fountain of youth” for blood stem cells. Three days after administration of the molecule, the stem cells presented an epigenome similar to the initial young cord-blood cells, whereas in the absence of UM171, these cells underwent premature epigenome aging.
As a result, patients transplanted with the rejuvenated cells very quickly experience an overall improvement in their quality of life as their blood cell counts are rapidly recovered. Not only does UM171 rejuvenate the cells, they also become more competent at producing an improved immune system. As a result, after six months, most patients no longer need immunosuppressants, normally needed to reverse the negative immunological impact of bone-marrow transplants."
Extract of UM171: the molecule that keeps on giving

CLINICAL TRIALS

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Fred Hutchinson / University of Washington Cancer Consortium
Seattle, Washington, United States

Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant
​Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
                           More clinical trials for UM171

​                                               See also Cure possible  for CML?